Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.80 |
| ▸ | ARG2 | P78540 | 4/20 | 0.70 |
| ▸ | ARG1 | P05089 | 3/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.62 |
| ▸ | GRM8 | O00222 | 1/20 | 0.62 |
| ▸ | GRM6 | O15303 | 1/20 | 0.62 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.62 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.62 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.62 |
| ▸ | GRM5 | P41594 | 1/20 | 0.62 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.62 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.62 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.62 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.62 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.62 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.62 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.62 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.62 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.62 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3239635 | 1.00 | GSR (0.80) | GSRARG2ARG1CYP1A2GRM8 | |
| SCHEMBL21689907 | 1.00 | GSR (0.80) | GSRARG2ARG1CYP1A2GRM8 | |
| SCHEMBL29268443 | 1.00 | GSR (0.80) | GSRARG2ARG1CYP1A2GRM8 | |
| SCHEMBL8893420 | 0.97 | GSR (0.76) | GSRARG2ARG1CYP1A2GRM8 | |
| Hydrochloric Acid SCHEMBL20541043 | 0.97 | GSR (0.76) | GSRARG2ARG1CYP1A2GRM8 | |
| SCHEMBL8894128 | 0.97 | GSR (0.76) | GSRARG2ARG1CYP1A2GRM8 | |
| Hydrochloric Acid SCHEMBL20541045 | 0.97 | GSR (0.76) | GSRARG2ARG1CYP1A2GRM8 | |
| Hydrochloric Acid SCHEMBL20541044 | 0.97 | GSR (0.76) | GSRARG2ARG1CYP1A2GRM8 | |
| SCHEMBL4848672 | 0.97 | GSR (0.76) | GSRARG2ARG1CYP1A2GRM8 | |
| SCHEMBL9829771 | 0.97 | GSR (0.76) | GSRARG2ARG1CYP1A2GRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022727-A1 | MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF ADIPATE, HEXAMETHYLENEDIAMINE AND 6-AMINOCAPROIC ACID | GENOMATICA INC (US) | 2023-01-26 | — | — | US | claimed |
| US-7427654-B1 | Degradable polymides | UNIVERSITY OF PUERTO RICO (US) | 2008-09-23 | — | — | US | claimed |
| CN-101250137-A | Preparation method of hexamethylene diamine dicarboxylic acid dihydroxy ester | PETROCHINA CO LTD (CN) | 2008-08-27 | — | — | CN | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| US-4401658-A | VACCINE ADJUVANTS, IMMUNOSTIMULANTS | RHONE-POULENC SANTE (FR) | 1983-08-30 | — | — | US | claimed |
| US-20260130895-A1 | METABOLISM ENHANCING COMPOSITIONS | Red Mountain Med Spa, LLC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4719381-A1 | LIGAND-POLAR DRUG CONJUGATES | Tripartite Therapeutics Inc. (TW) | 2026-04-08 | — | — | EP | disclosed |
| US-12577591-B2 | Microorganisms and methods for increasing co-factors | GENOMATICA, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12551470-B2 | Metabolism enhancing compositions | Red Mountain Med Spa, LLC (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260028651-A1 | METHOD OF PRODUCING & PROCESSING DIAMINES | AGAIN BIO APS (DK) | 2026-01-29 | — | — | US | disclosed |
| US-20260000597-A1 | ACETYLCHOLINE RECEPTOR INHIBITORY PEPTIDES AND USES THEREOF | SKINMED CO., LTD. (KR) | 2026-01-01 | — | — | US | disclosed |
| US-12503711-B2 | Method of producing and processing diamines to a diamine free base using a carbonate intermediate and an engineered microorganism | GENOMATICA, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| WO-1996012499-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
| CN-1107463-A | Asymmetrically substituted diaminodicarboxylic acid derivatives and a process for their preparation | HAFSLUND NYCOMED PHARMA (AT) | 1995-08-30 | — | — | CN | disclosed |
| US-4908475-A | Chemical intermediates | SMITHKLINE BECKMAN CORPORATION (US) | 1990-03-13 | — | — | US | disclosed |
| US-4810778-A | OLIGOPEPTIDES | SMITHKLINE BECKMAN CORPORATION (US) | 1989-03-07 | — | — | US | disclosed |
| US-4760052-A | 1,6-dicarba-vasopressin compounds | SMITHKLINE BECKMAN CORPORATION (US) | 1988-07-26 | — | — | US | disclosed |
| CN-87100308-A | Polypeptide compound | — | 1987-09-16 | — | — | CN | disclosed |
| EP-0231077-A2 | Polypeptide compounds | SMITHKLINE BECKMAN CORPORATION (US) | 1987-08-05 | — | — | EP | disclosed |
| US-4401658-A | VACCINE ADJUVANTS, IMMUNOSTIMULANTS | RHONE-POULENC SANTE (FR) | 1983-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000597-A1 | ACETYLCHOLINE RECEPTOR INHIBITORY PEPTIDES AND USES THEREOF | CHRNE, CHRNG, CHRND | GSR 1986/4885ARG2 2010/4885ARG1 1349/4885 |
| US-20260130895-A1 | METABOLISM ENHANCING COMPOSITIONS | GYS2, SLC19A1, SLC19A2 | GSR 204/4885ARG2 409/4885ARG1 1496/4885 |
| US-20260028651-A1 | METHOD OF PRODUCING & PROCESSING DIAMINES | DDC, DAO, ODC1 | GSR 2365/4885ARG2 1129/4885ARG1 688/4885 |
| US-12577591-B2 | Microorganisms and methods for increasing co-factors | ABAT, HADHB, MMAB | GSR 804/4885ARG2 1011/4885ARG1 4044/4885 |
| US-12551470-B2 | Metabolism enhancing compositions | BHMT, SLC19A2, GYS2 | GSR 202/4885ARG2 382/4885ARG1 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.